Important

Research Use Notice

All articles and product information provided on this website are for informational and educational purposes only. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Do not administer these products to humans or animals.

Product Documentation

Details, specifications, and documents

Description

Vesugen 20 mg: research material

Buy Vesugen 20 mg for laboratory research, supplied as lyophilized powder in one boxed 3 mL vial.

Vesugen is a synthetic tripeptide with the sequence Lys-Glu-Asp, abbreviated KED. It is investigated in cell-culture models, including experiments on vascular endothelial cells and markers associated with proliferation.

Choose the material and presentation

The selected vial contains a labeled 20 mg of material. Its 3 mL capacity identifies the container size, not a supplied solution volume or concentration.

Sequence order and length distinguish this material from related short peptides. KED is different from KEDG, KEDP and KEDW, each of which contains another amino-acid residue. Compare the complete sequence and supplied chemical form with the material used in your chosen study. Capsules, mixed tissue extracts and formulated solutions are different preparations.

Vesugen in endothelial-cell experiments

In an original vascular-cell study, researchers examined rat tissue explants and cultured aortic endothelial cells. The dissociated cells were compared at early and later culture passages. Ki-67 staining was used as a proliferation-associated readout.

The authors reported increases in Ki-67-positive area with Vesugen in the tested cultures. They also modeled possible interactions with promoter regions of the MKI67 gene. That docking analysis was computational; it did not directly demonstrate peptide-DNA binding inside cells.

The distinction between observation and explanation matters here. A change in a culture marker does not establish improved circulation, vascular repair or an anti-aging effect in people. Nor does a result from the study establish the activity of a particular supplied lot.

Product records and batch reports

Use the COA & Documents tab to review the available reports and product files. Match the compound, presentation and lot before relying on a batch report. Identity results, chromatographic purity and measured material content answer different questions.

Confirm the specifications needed for your laboratory workflow, including supplied chemical form and supported storage or handling conditions. Published biological findings and supplier analytical records serve different purposes; neither should be used as a substitute for the other.

Additional information

CAS No.

99469-43-9

Purity

≥99%

Synthesis Method

Solid-phase synthesis

Format

Lyophilized powder

Solubility

Water or validated laboratory buffer

Stability & Storage

Up to 24 months at -20°C. Avoid repeated freeze-thaw cycles.

Applications

In-vitro assay research, compound characterization, analytical method development

Appearance

White to off-white powder

Regulatory/Compliance

Not for human consumption. For research use only.

Safety Information

MSDS available upon request

COA & Documents

Independent lot testing

Vesugen 20mg Certificate of Analysis

This product has featured batch-specific third-party laboratory documentation. The Pure Lab Peptides summary presents selected source-report fields in a consistent format; the linked original laboratory report controls if any information differs.

Lot number
18854
Report number
39801
Date tested
September 17, 2026
Reported purity
99.892%
Labeled content
20 mg
DOWNLOADABLE RESOURCES

Product documents

Product information and laboratory resources. For lot-specific results, use the COA above.

PDF

Product & packaging information

Labeled amount, physical form and packaging for Vesugen 20mg.

Revision 0.4 · 2026-10-05Download PDF
PDF

Laboratory handling guide

General guidance for applicable lyophilized research materials. Not a product-specific SDS.

Revision 1.0 · 2026-09-22Download PDF
General guides & resources

Need Assistance?

Questions about product documentation?

Contact our support team for help with product records, lot information, orders or certificate verification.

Contact Support